Message :
Required fields
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA
®. The data were shared as an oral presentation at the 30
th Annual American Association of Clinical Endocrinology (AACE) Meeting being held virtually from May 26-29, 2021.
“The encouraging PROs data from the MPOWERED study further our understanding of the potential positive clinical impact that MYCAPSSA has for patients with acromegaly,” said Nienke Biermasz, M.D., Ph.D., Presenting Author. “These PROs provide important information to help physicians assess disease and treatment burden for patients treated with iSSAs and may provide the c
AACE e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting
NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23
rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30
th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29, 2021).
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.